NEW YORK (GenomeWeb News) – Molecular diagnostics developer DxS has received European Union approval to sell its TheraScreen K-RAS Mutation Kit for use on Roche's LightCycler 480 Instrument II.

DxS said that the CE-IVD Mark will enable the firm to sell the test, which is used to monitor patient response to Amgen's panitumumab (Vectibix) and Merck's cetuximab (Erbitux) drugs for colorectal cancer, in clinical settings in the EU.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Dog DNA testing finds that some purebreds might not truly be purebreds, Inside Edition reports.

Mary Beckerle has returned as director of the Huntsman Cancer Institute, according to ScienceInsider.

Smithsonian Magazine reports that environmental DNA sampling can be used to track elusive organisms.

In Genome Research this week: repetitive satellite DNA in the fruit fly, transcriptome map assembly pipeline, and more.